Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting

• Status: Completed
• Trial end date: 2016-03-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is a registry of renal cancer patients treated with Nexavar. It aims to evaluate the actual dosing of Nexavar in "real-life" setting vs. the prescribed dose.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Sorafenib

Criteria

Inclusion Criteria:

• Age >/= 18 years

• Diagnosis of renal cell carcinoma

• Failure of prior therapy with interferon-alfa (IFN) or interleukine-2 (IL-2) or disqualified from therapy with IFN/IL-2

• Patients in whom the oncologist has decide to start therapy with sorafenib.

Exclusion Criteria:

• Synonymous with contraindications to Nexavar.